mFOLFOX6: Clinical Trials

22 trials of mFOLFOX6, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 6 recruiting, 4 terminated, 2 active not recruiting. 22 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 122Completed 8, Recruiting 6, Terminated 4, Active not recruiting 2, Not yet recruiting 2
Phase 28Completed 4, Active not recruiting 2, Recruiting 2

Follow mFOLFOX6: new trials by email Literature Review of mFOLFOX6 trials Research Report on mFOLFOX6

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
GDC-7035, Panitumumab, mFOLFOX6 - Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Phase 1Not yet recruitingGenentech, Inc.3882026-11-302026-11-10
EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer
EMB-01, Irinotecan, TAS-102 - Unresectable/Metastatic Colorectal Cancer
Phase 1RecruitingShanghai EpimAb Biotherapeutics Co., Ltd.1202026-09-302026-10-16
A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer
Cetuximab, mFOLFOX6 - mCRC
Phase 1Not yet recruitingShanghai Henlius Biotech3872026-06-302026-04-24
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab - KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1RecruitingKestrel Therapeutics, Inc.5452026-04-212026-11-12
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin) - Non-Small Cell Lung Cancer, NSCLC
Phase 1RecruitingTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)6652025-03-312026-06-02
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
ALTA3263, cetuximab, mFOLFOX6 - Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Phase 1RecruitingAlterome Therapeutics, Inc.4482025-03-052026-10-26
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
cadonilimab, Trastuzumab, XELOX - Metastatic HER2 Positive Gastroesophageal Junction Cancer
Phase 1 / Phase 2RecruitingZhejiang Cancer Hospital902024-07-102024-10-21
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine - Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma
Phase 1 / Phase 2RecruitingBoehringer Ingelheim9102024-06-282026-11-16
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
ginisortamab, trifluridine/tipiracil, mFOLFOX6 - Advanced Solid Tumors
Phase 1 / Phase 2CompletedUCB Biopharma SRL932020-07-092025-05-29
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
TST001, Nivolumab Injection [Opdivo], mFOLFOX6 - Advanced Cancer, Gastric Cancer
Phase 1 / Phase 2Active not recruitingTranscenta Therapeutics (Hangzhou) Co., Ltd.1502020-05-282026-09-29
Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
nab-sirolimus - Colorectal Cancer Metastatic
Phase 1 / Phase 2CompletedAadi Bioscience, Inc.602018-07-012024-01-02
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
Bemarituzumab, Modified FOLFOX6 - Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic
Phase 1CompletedFive Prime Therapeutics, Inc.122017-11-302024-02-28
PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
PDR001, bevacizumab, mFOLFOX6 - Metastatic Colorectal Cancer
Phase 1TerminatedNovartis Pharmaceuticals12017-09-252021-10-12
Lidocaine for Oxaliplatin-induced Neuropathy
Lidocaine Hydrochloride, Placebo, FOLFOX regimen - Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy
Phase 1 / Phase 2CompletedWashington University School of Medicine262017-09-152022-03-09
Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
TSR-033, Dostarlimab, mFOLFOX6 - Neoplasms
Phase 1CompletedTesaro, Inc.1112017-08-082024-04-11
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
Monalizumab, Durvalumab, Cetuximab - Advanced Solid Tumors
Phase 1 / Phase 2Active not recruitingMedImmune LLC3832016-02-222026-06-15
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
CRLX101, Bevacizumab, mFOLFOX6 - Solid Tumors
Phase 1TerminatedNewLink Genetics Corporation412015-10-012020-05-28
Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma
Idelalisib, Nab-paclitaxel, mFOLFOX6 - Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
Phase 1TerminatedGilead Sciences162015-07-302021-04-02
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
BKM120, mFOLFOX6 - Advanced Solid Tumors, Metastatic Colorectal Cancer
Phase 1CompletedUNC Lineberger Comprehensive Cancer Center172012-05-012017-04-26
GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors
GDC-0980, bevacizumab, capecitabine - Solid Cancers
Phase 1CompletedGenentech, Inc.412011-07-012016-11-02

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Colorectal Neoplasms (11)  ·  Neoplasm Metastasis (5)  ·  Pancreatic Neoplasms (4)  ·  Colonic Neoplasms (3)  ·  Lung Neoplasms (3)  ·  Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Rectal Neoplasms (2)  ·  Stomach Neoplasms (2)  ·  Adenocarcinoma Of Esophagus (1)  ·  Biliary Tract Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Carcinoma (1)  ·  Cholangiocarcinoma (1)  ·  Cold Hypersensitivity (1)

Sponsors

Genentech, Inc. (2)  ·  Aadi Bioscience, Inc. (1)  ·  Alterome Therapeutics, Inc. (1)  ·  Amgen (1)  ·  Boehringer Ingelheim (1)  ·  Five Prime Therapeutics, Inc. (1)  ·  Gilead Sciences (1)  ·  Hoffmann-La Roche (1)  ·  Kestrel Therapeutics, Inc. (1)  ·  MedImmune LLC (1)  ·  NewLink Genetics Corporation (1)  ·  Novartis Pharmaceuticals (1)  ·  Shanghai EpimAb Biotherapeutics Co., Ltd. (1)  ·  Shanghai Henlius Biotech (1)  ·  Tesaro, Inc. (1)

Countries

United States (17)  ·  United Kingdom (4)  ·  China (3)  ·  France (3)  ·  Spain (3)  ·  Australia (2)  ·  Belgium (2)  ·  Italy (2)  ·  South Korea (2)  ·  Canada (1)  ·  Germany (1)  ·  Hungary (1)  ·  Japan (1)  ·  New Zealand (1)

Top investigators

Autumn McRee, MD (1)  ·  Charlie Qi, MD (1)  ·  Jieer Ying, MD (1)  ·  NewLink Ge (1)  ·  Simon Haroutounian, PhD (1)

Results publications

PMID 26032776, PMID 36852723, PMID 38084840, PMID 38309722, PMID 40016550, PMID 41108088, PMID 41790032

NIH funding

2016 (1), 2017 (1), 2019 (1)